These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15598035)

  • 1. Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
    Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Voigtmann R; Schwartz B; Brendel E; Christensen O; Haase CG; Strumberg D
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):650-1. PubMed ID: 15598035
    [No Abstract]   [Full Text] [Related]  

  • 2. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib: in hepatocellular carcinoma.
    Simpson D; Keating GM
    Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can sorafenib cause hypothyroidism?
    Robinson SI; Hobday TJ; Sathananthan A; Morris JC; McWilliams RR
    J Chemother; 2007 Jun; 19(3):352-3. PubMed ID: 17594936
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib prolongs survival, but what happens to the symptoms?
    Strebel BM
    J Hepatol; 2012 Jul; 57(1):222-3; author reply 223. PubMed ID: 22342632
    [No Abstract]   [Full Text] [Related]  

  • 7. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
    Pazo Cid RA; Lao J; Lanzuela M
    JAMA; 2011 Feb; 305(8):781; author reply 781. PubMed ID: 21343576
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 9. A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
    Spigel DR; Hainsworth JD; Burris HA; Molthrop DC; Peacock N; Kommor M; Vazquez ER; Greco FA; Yardley DA
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):280-6. PubMed ID: 21558987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 11. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 12. Sorafenib-induced destructive thyroiditis.
    Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
    Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
    [No Abstract]   [Full Text] [Related]  

  • 13. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
    El-Khoueiry AB; Rankin CJ; Ben-Josef E; Lenz HJ; Gold PJ; Hamilton RD; Govindarajan R; Eng C; Blanke CD
    Invest New Drugs; 2012 Aug; 30(4):1646-51. PubMed ID: 21748296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
    Richly H; Kupsch P; Passage K; Grubert M; Hilger RA; Kredtke S; Voliotis D; Scheulen ME; Seeber S; Strumberg D
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):620-1. PubMed ID: 14692720
    [No Abstract]   [Full Text] [Related]  

  • 16. All that glitters: sorafenib.
    Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
    Intern Med; 2011; 50(7):797. PubMed ID: 21467725
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting ELF in therapy of liver cancer.
    Cancer Biol Ther; 2007 Jul; 6(7):997. PubMed ID: 19358343
    [No Abstract]   [Full Text] [Related]  

  • 18. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
    Bellini E; Pia A; Brizzi MP; Tampellini M; Torta M; Terzolo M; Dogliotti L; Berruti A
    Ann Oncol; 2011 Apr; 22(4):988-990. PubMed ID: 21321087
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.